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Introduction: Migraine has consistently been associated with increased risk of ischemic stroke, 
while the evidence for a relation with other types of stroke or coronary outcomes is limited. We 
examined the association between migraine and stroke and acute coronary syndrome (ACS) 
subtypes and the influence of potential confounding factors.
Methods: All first-time hospital contacts for stroke (n=155,216) or ACS (n=97,799) were 
identified in Danish National Patient Registers and matched with 2 control groups of the 
background population. A hospital diagnosis of migraine and use of migraine medication were 
the main exposures and associations (odds ratios [OR]) were estimated using multiple logistic 
regression. Confounding was also addressed by including use of general headache medication 
as a negative control exposure.
Results: The diagnosis of migraine was associated with increased odds of both stroke (OR
crude
, 
age <50 years: 4.80 [95% CI: 3.75–6.21]; OR
crude, 
age ≥50 years:1.91 [95% CI: 1.67–2.19]) and 
ACS (OR
crude
:1.88 [95% CI: 1.53–2.32]), while the ORs for the associations between migraine 
medication and stroke and ACS were lower. Patients with a diagnosis of migraine or redeemed 
migraine medication had increased ORs of all stroke subtypes (ischemic, hemorrhagic stroke 
and transient ischemic attacks). The diagnosis of migraine was also associated with both angina 
and myocardial infarction (ST-elevation Myocardial Infarction [STEMI], non-STEMI and 
unspecified) with the highest OR for angina. These associations were not fully explained by 
adjustment for confounding co-variables or when compared with the negative control exposure 
that were assumed to be influenced by similar confounding factors, but no shared pathogenesis.
Conclusion: Hospital-diagnosed migraine was associated with all stroke and ACS subtypes, 
with ischemic stroke and angina having the highest odds. Confounding did not explain the 
associations.
Keywords: migraine medication, stroke, acute coronary syndrome, case-control study, confounding
Introduction
Migraine is a common neurological disorder with a prevalence of ~18%.1 An aura, 
presumably triggered by cortical spreading depression, is present in up to 30% of 
migraineurs usually during the hour preceding the headache.2 Migraine has traditionally 
been viewed as a benign chronic episodic condition. However, accumulating evidence 
from smaller population- or hospital-based case-control (n=72–626 stroke cases) and 
cohort (n=102–750 stroke outcomes) studies suggests that migraine, especially with 
aura, doubles the risk of ischemic stroke.2–6 Data from these observational studies 
have been subject to meta-analyses,7–10 of which the most recent7,10 showed associa-
tions between migraine and both ischemic and hemorrhagic stroke with overall pooled 
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odds ratios (OR) of 2.04 (95% CI: 1.72–2.43)7 and 1.48 
(95% CI:1.46–1.88),10 respectively. Furthermore, subgroup 
analyses have revealed significant interactions for gender, 
age, smoking and oral contraceptive use with higher risk 
estimates in women, patients below age 45 years, smokers 
and women using oral contraceptives.3–5
To date, no clear mechanisms of the increased risk of 
stroke among patients with migraine have been identified and 
several hypotheses have been suggested. They have mainly 
been related to hemodynamic, inflammatory, coagulation, 
endothelial and vascular factors and medication.2,4–6,11 These 
mechanisms are shared with other vascular diseases and 
recently, migraine has also been associated with increased 
risk of ischemic heart disease12,13 and it has been suggested 
that migraine should be viewed as a systemic disorder affect-
ing the endovascular system.5,6,11 However, while a number 
of studies have shown an association between migraine with 
aura and ischemic stroke, evidence is less consistent for 
hemorrhagic stroke, transient ischemic attacks (TIA), and 
ischemic heart disease as well for migraine without aura. In 
addition, many of the previous studies have only included a 
small number of confounding factors.
In the present study, we used data from 2 nationwide, 
register-based, case-control studies to examine the asso-
ciation between migraine with and without aura and stroke 
and acute coronary syndrome (ACS) subtypes. Based on 
the above evidence, we tested the following hypotheses: 
1) migraine is associated with increased risk of stroke and 
ACS with the strongest association for ischemic stroke, TIA, 
myocardial infarction and angina, and 2) the associations 
between migraine and these cardiovascular outcomes are 
partly explained by cardiovascular risk factors, and 3) the 
risk is higher in females, the youngest age group, and among 
users of oral contraceptives or hormone replacement, and 
lower in patients using anti-thrombotic medication. Finally, 
we addressed potential confounding in 2 ways: 1) by con-
sidering the above cardiovascular risk factors and 2) as sug-
gested by Gage et al,14 including a negative control exposure 
(use of general headache medication) with assumed similar 
confounding but no shared pathogenesis.
Methods
Study population
All first-time hospital contacts for ACS or stroke in subjects 
aged 15 years or above occurring in Denmark from January 
1, 2001 to December 31, 2009 or 2011, respectively, were 
included in the study. In total, 155,216 patients with stroke 
or TIA were identified in the nationwide Danish National 
Patient Registry (DNPR)15 and the Danish Stroke Registry 
by primary in- or out-patient diagnoses with the following 
International Classification of Disease version 10 (ICD-10) 
codes: I61 hemorrhagic stroke (n=14,843), I63 ischemic 
stroke (n=58,299), I64 unspecified stroke (n=73,715) and 
G45 TIA (n=8,359). In total, 97,799 patients with ACS were 
identified in the DNPR by the following ICD-10 codes: I20.0 
unstable angina pectoris (n=20,521), I21.0–I21.3 ST-eleva-
tion myocardial infarction (STEMI) (n=9,534), I21.4 non-
STEMI (n=25,058) and I21.9 unspecified acute myocardial 
infarction (AMI) (n=42,686). The DNPR provides full history 
of somatic diseases leading to hospital in- or out-patient visits 
by all citizens in Denmark since 1995.15 Two comparable 
control groups were sampled from the background population 
by matching with age, gender, and municipality at the time of 
stroke or ACS diagnosis using information from the Danish 
Civil Registration System (CPR). This register has allocated a 
unique personal identifier to everyone living in Denmark and 
keeps updated information on residency and vital status for 
each individual. The total number of subjects in the control 
groups was 156,905 and 99,618. The control groups were 
larger than the case group, as we excluded 1689 stroke and 
1819 ACS cases who showed up not being incident as they 
had a prior register-based stroke or ACS diagnosis. The study 
was approved by the Danish Data Protection Agency. All data 
were retrieved from administrative registers and informed 
consent was not required of participants.
Assessment of migraine
Migraine was defined by a diagnosis in the DNPR or the 
Danish Psychiatric Central Register and/or redemption of 
migraine specific acute abortive (termed primary) medica-
tion or migraine preventive (termed secondary) medication 
in the Register of Medicinal Products Statistics.16 Diagnosis 
and medication were identified by ICD-10 and Anatomic 
Therapeutical Chemical (ATC) Classification System prior to 
the stroke, ACS or matching date. The ICD-10 and ATC codes 
are provided in the second column in Table 1. Both primary 
and secondary migraine medication needed prescription from 
a physician and dates for refill of prescribed medicine were 
registered in the Medical Products Statistics.
Co-variables
Based on reviews of the literature,4–10 a number of socio-
demographic and clinical characteristics associated with 
migraine and cardiovascular disease were included. Informa-
tion on age and gender was obtained from the CPR, while 
data on highest achieved education were retrieved from 
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the Population Education Register. Education was grouped 
into basic (grades 7–9 of obligatory schooling), middle 
(high school, or vocational diploma) and higher (academic 
degree) education. Furthermore, diabetes mellitus, hyperten-
sion, alcohol-related disorders, COPD and depression were 
identified prior to stroke, ACS, or matching date by ICD-10 
codes and ATC-codes described in Table S1. Information 
on current or former use of oral contraceptives, hormone 
replacement therapy, anti-thrombotic and -platelet medica-
tion (acetylsalicylic acid, clopidogrel, and warfarin), or 
statins prior to diagnosis was retrieved from the Register of 
Medical Products Statistics using the ATC-codes provided 
in Table S1.
Statistical analyses
Differences in the distribution of main exposures and co-
variables between cases and controls were examined using 
chi-square test. Logistic regression analyses were carried out 
to calculate odds ratios (OR) and 95% CI for the association 
between migraine and stroke or ACS, and to adjust the esti-
mates for the potentially confounding factors. As cases and 
controls represented the general population and exposure 
variables were collected prospectively, we assumed that the 
ORs will approximate relative risks. Models were tested by 
the Hosmer–Lemeshow chi-square test, which indicated 
reasonable fit. The influence of hormone use (oral contracep-
tives or hormone replacement therapy) was examined twice, 
both in models restricted to women and in models with men 
in the group coded as never. In models with <50 exposed, 
comorbidities and anti-thrombotic medication were entered 
as 2 combined yes/no variables. All analyses were repeated 
for each stroke or ACS sub-type. Any statistical interactions 
between migraine exposures and co-variables (age, gender, 
hormone use, and anti-thrombotic medication) were exam-
ined by adding an interaction term between migraine and 
each co-variable in the logistic models. Models with and 
without the interaction term were compared using likelihood 
ratio tests, thus interactions were tested on a multiplicative 
scale. Preliminary data analysis showed that OR differed for 
patients around age 50 years and the analyses were stratified 
accordingly. In supplementary analyses of confounding, we 
used general headache medication use (ATC codes provided 
in Table 1) as negative control exposure as this measure may 
have similar confounding as migraine but no assumed shared 
pathogenesis.14 Thus, users of general headache medication 
(nonsteroidal anti-inflammatory drugs) seemed to have more 
comorbidities than non-users,17 and the pattern of comorbidity 
seemed to be similar in pain medication users with and without T
ab
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chronic headache.18 Consequently, if the association between 
migraine and stroke and ACS was due to confounding, we 
expected to find a similar association between the negative 
control exposure and stroke and ACS, respectively. A sig-
nificance level of 5% was used and analyses were performed 
in STATA 14 (StataCorp LLC, College Station, TX, USA).
Results
Migraine and stroke
Among the 155,216 stroke patients, 974 (0.63%) had a 
diagnosis of migraine and 5362 (3.45%) had used primary 
migraine medication. Among controls, the corresponding 
numbers were 403 (0.26%) and 4675 (2.98%), respectively 
(Figure 1).
In crude analyses, stroke patients had increased likeli-
hood of having a diagnosis of migraine (OR
crude
, all types, 
age <50 years
:
 4.80 [95% CI: 3.75–6.21]); OR
crude, 
all types, 
age ≥50 years 1.91 [95% CI: 1.67–2.19]). This was seen 
both for migraine with and without aura. Stroke patients also 
had increased odds of using primary migraine medication 
(OR: 1.17 [95% CI: 1.11–1.21]) (Figure 1). Also, ORs were 
increased for both triptan (OR: 1.19 [95% CI: 1.13–1.24]) 
and ergotamine use (OR: 1.08 [95% CI:1.00–1.17]), but not 
significantly for ergotamine (Figure 1).
In both cases and controls, diagnosis of migraine and use 
of migraine medication were most frequent in individuals 
younger than 50 years, women, the highest educated, indi-
viduals with a diagnosis of depression or COPD, and among 
women who used hormones (Table S2). Adjustment for these 
cardiovascular risk factors attenuated the OR estimates, 
especially in analyses of migraine with aura (Figure 1). All 
analyses were repeated for the different stroke subtypes, 
which showed that diagnosis of migraine or use of migraine 
medication were associated with increased odds for all stroke 
subtypes (Table 2). For migraine with aura, the OR was low-
est for hemorrhagic stroke and highest for TIA (p test for 
interaction=0.02), but the statistical power of the analyses 
was, despite the large sample size, limited due to the low 
number of individuals with diagnosis of migraine with aura. 
Consequently, the estimates had very wide CI.
In patients with migraine, 53.3% used primary migraine 
medication, but use of primary medication did not interact 
with the association between diagnosis of migraine and 
stroke. In both men and women, odds of having diagnosis of 
migraine were – as noted above – higher in stroke patients 
<50 years than in the older age group. The interaction terms 
were, however, not significant for gender, comorbidity, 
nor anti-thrombotic treatment (results not shown). Female 
Figure 1 Associations (Crude and Adjusted OR and 95% CI) between migraine and stroke in 155,216 stroke patients and 156,905 controls.
Notes: Adjusted for age, gender, education, diabetes mellitus, hypertension, alcohol related disorders, chronic obstructive pulmonary disease, depression, use of oral 
contraceptives, hormone replacement therapy, and antithrombotic medication (acetylsalicylic acid, clopidogrel, and warfarin) and statin prior to diagnosis.
Stroke
Migraine diagnosis
All diagnoses, <50 years
Migraine without aura, ≥50 years
Triptans
Clonidine
Calcium-antagonists
Antiepileptics
Betablockers
Diagnosis
General headache medication
Primary migraine medicaion
Secondary migraine medication
Other types of headache
All medications
All medications
Ergotamine
Migraine without aura, <50 years
Migraine with aura, <50 years
All diagnoses, ≥50 years
Migraine with aura, ≥≥50 years
Population controls,
Crude OR (95% CI) Adjusted OR (95% CI)
Stroke cases,
N (%)
360 (0.23)
614 (0.40)
79 (0.05) 4.80 (3.75–6.21) 4.28 (3.33–5.51)
1.77 (1.54–2.03)
1.94 (1.54–2.47)
1.46 (1.25–1.70)
4.42 (3.27–5.93)
1.68 (1.44–1.96)
1.13 (1.08–1.18)
1.21 (1.15–1.27)
1.06 (0.98–1.14)
1.13 (1.09–1.16)
0.99 (0.93–1.06)
1.19 (0.96–1.48)
1.51 (1.41–1.63)
1.06 (1.02–1.11)
1.27 (1.12–1.44)
1.00 (0.98–1.02)
1.91 (1.67–2.19)
3.91 (3.41–6.57)
2.19 (1.61–3.01)
5.09 (3.81–6.91)
1.84 (1.58–2.15)
1.17 (1.11–1.21)
1.19 (1.13–1.24)
1.08 (1.00–1.17)
1.28 (1.24–1.32)
1.12 (1.65–1.20)
1.36 (1.01–1.69)
1.92 (1.78–2.06)
1.19 (1.15–1.24)
1.52 (1.34–1.72)
0.99 (0.98–1.01)
83 (0.05)
62 (0.04)
324 (0.21)
22 (0.01)
135 (0.09)
277 (0.18)
479 (0.31) 262 (0.17)
4675 (2.98)
3392 (2.16)
1283 (0.82)
5362 (3.45)
3980 (2.56)
1382 (0.89)
10,303 (6.64)
1954 (1.26)
207 (0.13)
2140 (1.38)
6468 (4.17)
673 (0.43)
20,375 (13.13) 20,640 (13.15)
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
447 (0.28)
5503 (3.51)
1133 (0.72)
154 (0.10)
1761 (1.12)
8239 (5.25)
57 (0.04)
N (%)
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stroke patients who had used oral contraceptives or hormone 
replacement therapy seemed to have increased likelihood 
of being diagnosed with migraine compared with females 
with no history of hormone use but this potential interaction 
vanished when age was accounted for. All tests for statistical 
interaction between migraine medication use and co-variables 
had p values >0.10.
The comparison of migraine indicators and the negative 
control exposure (use of general headache medication) in 
Table 3 showed that patients with diagnosis of migraine had 
1.8 times higher odds of stroke than those who used general 
headache medication. Smaller, relative differences were seen 
for other migraine measures.
Migraine and ACS
Among the 97,799 patients with ACS, 268 (0.27%) had 
diagnosis of migraine and 1814 (1.85%) had used primary 
migraine medication. Among controls, the corresponding 
numbers were 145 (0.15%) and 1729 (1.78%), respectively 
(Figure 2).
In crude analyses, ACS patients had increased likeli-
hood of being diagnosed with migraine (OR; 1.88 [95% 
CI: 1.53–2.32]) in addition to a somewhat lower likelihood 
of using primary migraine medication (OR: 1.07 [95% CI: 
1.00–1.44]), which was most evident for triptan use (OR: 
1.10 [95% CI: 1.02–1.18]) (Figure 2).
Among ACS cases and controls, diagnosis of migraine 
and use of migraine medication were most frequent among 
individuals <50 years, women, the highest educated, indi-
viduals with a diagnosis of depression or COPD, and among 
women who used hormones (Table S3). Adjustment for 
these cardiovascular risk factors slightly attenuated the ORs 
(Figure 2).
Analyses of ACS subtypes showed that a diagnosis of 
migraine was associated with increased odds for both unsta-
ble angina and AMI (STEMI, non-STEMI and unspecified), 
while primary migraine medication was only associated with 
increased odds for unstable angina (Table 4). Patients with 
unstable angina had higher likelihood of having a diagnosis 
of migraine with aura than patients with AMI (OR: 5.40 [95% 
CI: 2.05–17.97] and OR: 1.46 [95% CI: 0.86–2.50], p test 
for interaction=0.02), but the estimates were imprecisely 
measured due to the low number of individuals.
The 40.7% of patients with diagnosis of migraine, 
who used primary migraine medication, seemed to have 
lower odds of ACS (OR: 1.42 [95% CI: 1.04–1.97]) than 
migraineurs who had not used primary migraine medication 
(OR: 2.28 [95% CI: 1.72–3.06]). However, this interaction T
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vanished after adjustment for co-variables. Similarly, all 
other tests for statistical interaction between migraine and 
co-variables were insignificant.
Table 3 shows that patients with a diagnosis of migraine 
had >2 times higher odds of ACS than users of general head-
ache medication. Similar smaller relative differences were 
seen for migraine medication.
Discussion
The present large, register-based case-control study showed 
that hospital diagnosis of migraine was clearly associated 
with increased odds of both stroke and ACS. Furthermore, 
use of triptans was also associated with slightly higher 
odds of stroke and ACS while use of ergotamine was not. 
A diagnosis of migraine or use of migraine medication was 
associated with increased risk of all stroke and ACS sub-
types with higher estimates for migraine with aura and TIA 
and unstable angina, however, in these analyses, estimates 
were hampered by lack of power. The associations between 
diagnosis of migraine and all stroke subtypes were higher 
in the youngest age group (<50 years), while there was no 
statistical interaction between migraine and gender or use of 
oral contraceptives on a multiplicative scale.
Our study confirms the results from a number of studies 
showing that migraine is a risk factor for ischemic stroke.2,3–7 
The present study also supports the fewer studies that indicate 
that migraine increases the risk of hemorrhagic stroke.10 
We cannot exclude that the detected association between 
migraine and TIA is a spurious relation as it can be difficult 
to differentiate between migraine and TIA.4 In accordance 
with a few previous studies,12 diagnosis of migraine also 
seemed to increase the risk of ACS in the present study and 
this relation was not explained by adjustment for cardiovas-
cular risk factors.
We used primary migraine medication (triptan and ergota-
mine) as proxy measures for migraine, but only triptan use 
seemed to be weakly associated with stroke. This finding is 
comparable with the results from a recent Danish register-
based cohort study on the association between triptan use 
and stroke.19 In this study, triptans were associated with 
increased risk of ischemic stroke (Relative Risk [RR]; 1.07 
Figure 2 Associations (Crude and Adjusted odds ratio [OR] and 95% CI) between migraine and acute coronary syndrome (ACS) in 97,799 ACS patients and 99,618 controls.
Notes: Adjusted for age, gender, education, diabetes mellitus, hypertension, alcohol related disorders, chronic obstructive pulmonary disease, depression, use of oral 
contraceptives, hormone replacement therapy, and antithrombotic medication (acetylsalicylic acid, clopidogrel, and warfarin) and statin prior to diagnosis.
Abbreviation: ACS, acute coronary syndrome.
Acute coronary syndrome
ACS cases,
N (%)
Population controls,
N (%) Crude OR (95% CI) Adjusted OR (95% CI)
Migraine diagnosis
Diagnosis
General headache medication
Other types of headache
Triptans
Primary migraine medication
All medications
Ergotamine
Clonidine
Calcium-antagonists
Antiepileptics
Betablockers
Secondary migraine medication
All medications
Migraine with aura
All diagnoses 268 (0.27) 145 (0.15) 1.88 (1.53–2.32) 1.69 (1.36–2.09)
2.18 (1.38–3.45)
1.56 (1.22–1.99)
1.03 (0.96–1.10)
1.15 (1.07–1.25)
0.88 (0.74–1.05)
1.03 (0.98–1.08)
1.12 (0.98–1.29)
1.42 (0.98–1.78)
0.94 (0.83–1.07)
1.01 (0.96–1.08)
1.29 (1.04–1.61)
1.10 (1.07–1.13)
2.13 (1.37–3.39)
1.81 (1.43–2.30)
1.07 (1.00–1.44)
1.10 (1.02–1.18)
0.90 (0.76–1.06)
1.14 (1.09–1.19)
1.24 (1.10–1.41)
1.39 (0.82–2.38)
1.21 (1.08–1.35)
1.11 (1.06–1.17)
1.69 (1.37–2.09)
1.10 (1.07–1.13)
31 (0.03)
114 (0.11)
1729 (1.74)
1421 (1.43)
308 (0.31)
4182 (4.20)
494 (0.50)
27 (0.03)
596 (0.60)
3154 (0.15)
148 (0.15)
12,668 (12.72)
0 1 2 3 4 5 0 1 2 3 4 5
65 (0.07)
203 (0.21)
1814 (1.85)
1541 (1.58)
273 (0.28)
4669 (4.77)
604 (0.62)
37 (0.04)
707 (0.72)
3449 (3.53)
246 (0.25)
13,521 (13.85)
Migraine without aura
Table 3 OR and 95% CI for migraine diagnosis, migraine 
medication use and other types of headache compared with 
general headache medication use in stroke and acute coronary 
syndrome patients versus controls
Migraine measures Stroke, OR  
95% CI
Acute coronary 
syndrome, OR  
95% CI
Migraine diagnosis 1.75 (1.41–2.13) 2.47 (2.19–2.17)
Primary migraine medication 0.96 (0.90–1.40) 1.11 (1.06–1.16)
Secondary migraine medication 1.04 (0.99–1.09) 1.26 (1.21–1.31)
Other types of headache 1.52 (1.21–1.92) 1.56 (1.35–1.80)
General headache medication 1 1
None of above 0.90 (0.88–0.92) 0.99 (0.97–1.01)
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[95% CI:1.00–1.14]) and with hemorrhagic stroke in women 
(RR; 1.41 [95% CI: 1.11–1.79]). In the present study, triptan 
use was associated with increased odds of angina but not with 
myocardial infarction. This might reflect that triptans seemed 
to trigger chest discomfort,20 which could be a potential 
source of bias. Our results seem to support the conclusions 
in a recent systematic review of the few observational stud-
ies investigating adverse cardiovascular events associated 
with triptan and ergotamine. The review study showed no 
clear evidence of prescribed use of triptan or ergotamine 
increases the risk of serious ischemic complications.21 For 
both stroke and ACS, the association between primary 
migraine medication use and each endpoint was weaker than 
the association for a hospital diagnosis of migraine. Patients 
with migraine solely identified by medication and without 
a hospital diagnosis most likely represent milder cases and 
the lower risk estimates could therefore suggest some degree 
of dose–response relation between severity of migraine and 
cardiovascular events. Consequently, our study could indicate 
that the increases in odds represent disease severity rather 
than drug-related phenomena.
We replicated the previous findings of a stronger associa-
tion of diagnosis of migraine with all stroke subtypes in the 
youngest age group. For migraine with aura, the estimate for 
the youngest age group was higher than reported in recent 
meta-analyses. However, again this might reflect that our 
study is based on hospital diagnoses. Our analyses did not 
support the reports of higher odds estimated in females and 
users of contraceptives.4,6,7 Thus, in our study, a presumed 
interaction with hormone use vanished when the data were 
further stratified on age. Unfortunately, we had no informa-
tion on current smoking, which might also influence the effect 
of migraine on stroke risk. We used COPD as proxy marker 
for heavy smoking but admit that this is a less valid measure 
of current smoking habits. Our study did not support our 
Table 4 The associations (adjusted OR and 95% CI) of migraine diagnosis and medication with acute coronary heart syndrome sub 
types
Migraine measures Angina (n=20,521) Acute myocardial infarction* (n=77,278) 
Crude OR 95% CI Adjusted OR 95% CI Crude OR 95% CI Adjusted OR 95% CI
Migraine diagnosis 2.75 (1.86–4.16) 2.25 (1.48–3.48) 1.56 (1.22–2.01) 1.32 (1.02–1.71)
Migraine with aura 5.40 (2.05–17.97) 5.32 (1.98–14.33) 1.46 (0.86–2.50) 1.51 (0.88–2.57)
Migraine without aura or unspecified 2.32 (1.50–3.67) 2.10 (1.32–3.34) 1.59 (1.20–2.13) 1.36 (1.01–1.82)
Primary migraine medication 1.49 (1.31–1.68) 1.47 (1.28–1.68) 0.93 (0.86–1.01) 0.90 (0.82–1.00)
Triptans 1.59 (1.39–1.82) 1.57 (1.36–1.81) 0.94 (0.86–1.03) 0.92 (0.84–1.01)
Ergotamine 0.97 (0.69–1.35) 0.97 (0.68–1.38) 0.89 (0.93–1.09) 0.87 (0.71–1.07)
Secondary migraine medication 1.48 (1.35–1.62) 1.30 (1.17–1.13) 1.05 (0.99–1.10) 0.94 (0.89–1.00)
Notes: Adjusted for gender, age, education, diabetes, hypertension, alcohol related disorder, chronic obstructive pulmonary disease, depression, use of oral contraceptives, 
hormone replacement therapy, and antithrombotic medication (acetylsalicylic acid, clopidogrel, and warfarin) and statins prior to diagnosis; *STEMI, non-STEMI and unspecified.
Abbreviation: STEMI, ST-elevation myocardial infarction.
hypothesis that cardiovascular risk factors, including use of 
anti-thrombotic medication would influence the association 
between migraine and cardiovascular outcomes.
The mechanisms linking migraine and cardiovascular 
diseases have been discussed in several reviews,2,5,6,11,22 and 
the most recent suggests that vascular dysfunction or small 
vessel disease might be important.6,19,23 Thrombotic mecha-
nisms have also been suggested to link arterial dysfunction 
and vascular events, but in the present study, cardiovascular 
risk factors, including anti-thrombotic and -platelet treatment 
only explained a smaller part of the association between 
migraine and stroke and ACS, respectively.
The present study has strengths and limitations. First, 
the study was based on information on all incident strokes 
and ACS events from nationwide registers with high valid-
ity of stroke and ACS diagnoses and virtually without any 
losses.15,24,25 We had prospectively collected exposure data, 
which did not rely on patients’ recall, making non-response 
and information bias unlikely explanations for our find-
ings. Our definition of migraine was based on both hospital 
diagnoses and migraine medication prescription records 
and consequently, we might mainly have the most severe 
migraine cases. Thus, the results may not be transferable to 
milder cases. However, our estimates are comparable with 
those in previous reports based on validated questionnaires or 
physicians’ diagnosis. An observational study as the present 
cannot answer whether the associations between migraine 
and stroke and ACS are caused by the exposure itself or 
whether migraine is a marker for adverse work and social 
environment, health or health behavior. It should, however, be 
highlighted that the detected associations were not explained 
by cardiovascular risk factors, although, we did not have 
information on smoking and serum lipids in the register data. 
On the other hand, we brought a more unspecific headache 
exposure into the analyses as  negative control exposure. 
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We assumed that these individuals in many ways might be 
similar to those with migraine.18 Use of general headache 
medication was also associated with increased risk of ACS, 
which could suggest that our estimates were hampered by 
residual confounding from unmeasured risk factors such as 
work and social environment and health behavior. However, 
when migraineurs’ odds for stroke or ACS were compared 
with users of headache medication, thus accounting for 
assumed shared confounders (Table 3), the ORs for migraine 
remained elevated. This could suggest that the relation 
between migraine and the cardiovascular outcomes are due 
to shared pathogenesis and not explained by confounding. 
Finally, although the study was based on a large number of 
cases, the exposure was infrequent and the study did not have 
sufficient power to detect differences in odds between that 
is, migraine with aura and subtypes.
In conclusion, hospital-diagnosed migraine was asso-
ciated with stroke and ACS independent of subtype with 
ischemic stroke and unstable angina having the highest odds. 
Age interacted with the association between a diagnosis 
of migraine and stroke, and the youngest age group had 
the highest odds. The associations were not explained by 
adjustment for confounding factors or when compared with 
general headache medication use with similar confounding 
but no assumed shared pathogenesis. Our results also indi-
cate a degree of dose–response relation between severity of 
migraine and risk of cardiovascular events. Thus, clinicians 
should be aware of young patients with severe migraine with 
aura who seem to pose a risk for adverse vascular events.
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Supplementary material
Table S1 ICD 10 and ATC codes used for generation of variables measuring comorbidity, hormones and anti-thrombotic medication
Variables ICD-10 ATC 
Hypertension I10–I15 C02; C03; C08; C09
Chronic obstructive pulmonary disease J40–J47; J96.1; J98.1–2 R03
Diabetes E10; E11; E14; H36.0 A10
Alcohol abuse F10; K70; T51; G31.2; G62.1; G72.1; I42.6; K29.2; K86.0; 
Z72.1; I48.6
N07BB
Depression F31–F33, F34 N06A
Oral contraceptives G03A
Hormone replacement therapy G03C; G03F
Acetylsalicylic acid B01AC06, B01AC56, N02BA01, N02BA51
Statins C10AA
Clopidogrel B01AC22, B01AC04
Warfarin B01AA03, B01AA04
Abbreviation: ATC, anatomic therapeutical chemical.
Table S2 The distribution of covariables in relation to migraine diagnosis or medication in 155,216 first-time stroke patients and 
156,905 population controls in Denmark 2001–2011
Variables Stroke patients Population controls
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
Gender
Men 78,435 (50.53) 279 (0.36) 1592 (2.03) 79 418 (50.62) 130 (0.16) 1431 (1.80)
Women 76,781 (49.47) 695 (0.91) 3770 (4.91) 77,487 (49.30) 273 (0.35) 3244 (4.19)
Age (years)
<50 13,599 (8.76) 360 (2.65) 1268 (9.10) 14,035 (8.94) 79 (0.56) 827 (5.89)
50–69 53,887 (34.72) 386 (0.72) 2488 (4.62) 55,456 (35.34) 207 (0.37) 2346 (4.23)
≥70 87,730 (56.52) 228 (0.26) 1636 (1.86) 87,414 (55.71) 117 (0.13) 1499 (1.71)
Education
Higher 15,751 (10.15) 152 (0.97) 830 (5.27) 20,730 (13.21) 88 (0.42) 1730 (2.81)
Middle 46,735 (30.11) 334 (0.71) 1897 (4.06) 48,809 (31.11) 134 (0.27) 1697 (3.48)
Basic 65,941 (42.48) 419 (0.64) 2261 (3.43) 61,606 (39.26) 156 (0.25) 1730 (2.81)
Unknown 26,789 (17.26) 67 (0.25) 375 (1.40) 25,760 (16.42) 25 (0.10) 290 (1.13)
Diabetes
No 136,272 (87.80) 885 (0.65) 4907 (3.60) 144,991 (92.41) 380 (0.26) 4449 (3.07)
Yes 18,944 (12.20) 189 (1.00) 455 (2.40) 11,914 (7.59) 23 (0.19) 226 (1.90)
Hypertension
No 56,310 (36.28) 428 (0.76) 2051 (3.64) 76,757 (48.92) 170 (0.22) 2266 (2.95)
Yes 98,906 (63.72) 546 (0.55) 3311 (3.35) 80,148 (51.08) 233 (0.29) 2409 (3.01)
Chronic obstructive pulmonary disease
No 114,881 (74.00) 598 (0.52) 3329 (2.90) 121,645 (79.53) 268 (0.22) 3242 (2.67)
Yes 40,335 (26.00) 376 (0.93) 2033 (5.04) 35,260 (22.47) 135 (0.38) 1433 (4.06)
Major depression
No 111,305 (71.71) 510 (0.46) 2890 (2.60) 124,625 (79.43) 207 (0.17) 3070 (2.46)
Yes 43,911 (28.29) 464 (1.06) 2472 (5.63) 32,280 (20.57) 196 (0.61) 1605 (4.97)
Alcohol abuse
No 143,704 (92.58) 894 (0.62) 4929 (3.43) 152,083 (96.93) 391 (0.26) 4553 (2.99)
Yes 11,512 (7.42) 80 (0.69) 433 (3.76) 4822 (3.07) 12 (0.25) 122 (2.53)
Oral contraceptives (women)
No 71,205 (92.74) 470 (0.66) 2914 (4.09) 71,803 (92.66) 215 (0.30) 2648 (3.69)
Yes 5576 (7.26) 225 (4.04) 856 (15.35) 5684(7.34) 58 (1.02) 596 (10.49)
Hormone replacement therapy (women)
No 49,542 (69.52) 396 (0.80) 1944 (3.92) 50,082 (64.63) 124 (0.25) 1629 (3.25)
Yes 27,239 (35.48) 297 (1.09) 1826 (6.70) 27,405 (35.37) 149 (0.54) 1615 (5.89)
(Continued)
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 1
5-
Fe
b-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
448
Osler et al
Variables Stroke patients Population controls
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
Medication with anti-thrombotic properties ASA
No 132,890 (85.62) 596 (0.66) 3384 (3.72) 124,164 (79.13) 275 (0.25) 3559 (3.19)
Yes 22,326 (14.38) 378 (0.59) 1978 (3.08) 32,741 (20.87) 128 (0.28) 1116 (2.47)
Clopidogrel
No 149,643(96.64) 902 (0.60) 5152 (3.44) 153,142 (97.60) 389 (0.25) 4583 (2.99)
Yes 5573 (3.36) 72 (1.29) 210 (3.77) 3763 (2.40) 14 (0.37) 92 (2.44)
Warfarin
No 140,268 (90.37) 903 (0.64) 4981 (3.55) 147,418 (93.95) 389 (0.26) 4476 (3.04)
Yes 14,948 (9.63) 71 (0.47) 381 (2.55) 9487 (6.05) 14 (0.15) 199 (2.10)
Statin
No 125,707 (80.99) 741 (0.59) 4288 (3.41) 132,401 (84.38) 329 (0.25) 3948 (2.98)
Yes 29,509 (19.01) 233 (0.79) 1074 (3.64) 24,504 (15.62) 74 (0.30) 727 (2.97)
Abbreviation: ASA, acetylsalicylic acid.
Table S3 The distribution of covariables in relation to migraine diagnosis or medication in 97,799 Danish patients with first time acute 
coronary heart syndrome (ACS) and 99,618 population controls in Denmark 2001–2009.
Variables ACS patients Population controls
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
Gender
Men 60,365 (61.72) 99 (0.16) 692 (1.15) 61,548 (61.78) 64 (0.10) 668 (1.09)
Women 37,434 (38.28) 169 (0.45) 1122 (3.00) 38,070 (38.22) 81 (0.21) 1061 (2.79)
Age (year)
<50 10,553 (10.75) 70 (0.66) 479 (4.54) 10,764 (21.38) 31 (0.29) 356 (3.31)
50–69 39,924 (40.81) 125 (0.31) 957 (2.40) 40,736 (40.87) 77 (0.19) 926 (2.27)
≥70 47,322 (48.45) 73 (0.15) 378 (0.80) 48,118 (48.34) 37 (0.08) 447 (0.93)
Education
Higher 9641 (8.85) 30 (0.31) 303 (3.13) 13,922 (13.98) 21 (0.15) 380 (2.73)
Middle 31,728 (32.54) 98 (0.31) 607 (1.91) 33,406 (33.54) 45 (0.13) 653 (1.95)
Basic 41,549 (42.50) 116 (0.28) 780 (1.80) 37,721 (37.87) 69 (0.18) 598 (1.59)
Unknown 14,881 (15.07) 24 (0.10) 124 (0.84) 14,569 (14.62) 10 (0.07) 98 (0.67)
Diabetes
No 84,602 (86.74) 244 (0.29) 1652 (1.95) 92,718 (93.07) 134 (0.14) 1647 (1.78)
Yes 12,929 (13.26) 24 (0.19) 162 (1.25) 6900 (6.93) 11 (0.16) 82 (1.19)
Hypertension
No 40,342 (41.25) 101 (0.25) 786 (1.95) 56,415 (56.63) 77 (0.14) 1032 (1.83)
Yes 57,457 (58.75) 167 (0.29) 1028 (1.79) 43,203 (43.37) 68 (0.16) 697 (1.61)
Chronic obstructive pulmonary disease
No 76,701 (78.43) 196 (0.26) 1276 (1.66) 84,068 (84.39) 118 (0.14) 1391 (1.65)
Yes 21,098 (21.57) 72 (0.34) 538 (2.55) 15,550 (15.61) 27 (0.17) 338 (2.17)
Major depression
No 73,603 (75.26) 127 (0.17) 1015 (1.38) 79,767 (80.07) 87 (0.11) 1152 (1.44)
Yes 24,196 (24.74) 141 (0.58) 799 (3.30) 19,851 (19.93) 58 (0.29) 577 (2.91)
Alcohol abuse
No 94,474 (96.60) 255 (0.27) 1727 (1.83) 96,954 (97.33) 143 (0.15) 1696 (1.75)
Yes 3325 (3.40) 13 (0.39) 87 (2.62) 2664 (2.67) 2 (0.08) 33 (1.24)
Oral contraceptives (women)
No 35,110 (93.79) 141 (0.40) 898 (2.56) 35,717 (93.82) 66 (0.18) 885 (2.48)
Yes 2324 (6.21) 28 (1.20) 224 (9.64) 2353 (6.18) 15 (0.64) 176 (7.48)
Hormone replacement therapy (women)
No 24,002 (64.12) 90 (0.37) 576 (2.40) 25,009 (65.69) 44 (0.18) 562 (2.25)
Yes 13,432 (35.88) 79 (0.59) 546 (4.06) 13,061 (34.31) 37 (0.28) 499 (3.82)
Table S2 (Continued)
(Continued)
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Variables ACS patients Population controls
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
N (%) n (%) with 
migraine 
diagnosis
n (%) used 
migraine 
medication
Medication with anti-thrombotic properties ASA
No 56,315 (57.58) 147 (0.26) 1183 (2.10) 73,363 (73.64) 95 (0.13) 1354 (1.85)
Yes 41,484 (42.42) 121 (0.29) 631 (1.52) 26,255 (26.36) 50 (0.19) 375 (1.43)
Clopidogrel
No 94,509 (96.64) 251 (0.27) 1763 (1.87) 98,749 (99.13) 142 (0.14) 1709 (1.73)
Yes 3290 (3.36) 17 (0.52) 51 (1.55) 869 (0.97) 3 (0.35) 20 (2.30)
Warfarin
No 90,381 (92.42) 248 (0.27) 1733 (1.92) 93,910 (94.27) 137 (0.15) 1671 (1.78)
Yes 7418 (7.58) 20 (0.27) 81 (1.09) 5708 (5.73) 8 (0.14) 58 (1.02)
Statin
No 76,050 (77.76) 193 (0.25) 1409 (1.85) 87,884 (88.22) 121 (0.14) 1544 (1.76)
Yes 21,749 (22.24) 75 (0.34) 405 (1.86) 11,734 (11.78) 24 (0.20) 185 (1.58)
Abbreviation: ASA, acetylsalicylic acid.
Table S3 (Continued)
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